Abstract
Introduction: Alopecia is a frequent reason for consultation and is often associated with psychological, self-esteem, and quality of life (QoL) impact, particularly in women. To date, QoL assessment studies including all alopecia types are lacking. This study evaluated QoL and sensitivity to change of the Skindex-29 and the Dermatology Life Quality Index (DLQI) in these. Methods: This was an observational study with a longitudinal design, including two measurements over time and prospective data. It was carried out in four outpatient centers in Medellín, between 2023 and 2024. We included sociodemographic and clinical data, as well as the DLQI and Skindex-29 QoL questionnaires before and after treatment. Results: Participation of women was 51%; the most frequent types of alopecia were androgenic alopecia (52%), alopecia areata (AA) (19%), and telogen effluvium (TE) (9%). The alopecia types with the greatest impact on QoL (pretreatment) measured through the DLQI and the Skindex-29, respectively, were TE (10.29 [±9.32] and 40.39 [±32.04]), AA (9.27 [±9.13], and 33.91 [±26.47]), dissecting cellulitis (8.67 [±8.33] and 29.6 [±15.33]), and lichen planus pilaris (6.75 [±6.55] and 6.75 [±6.55]). Conclusion: The version validated in Colombia of the Skindex-29 and the Colombian Spanish version of the DLQI showed a moderate responsiveness when evaluating the QoL of patients with scarring and non-scarring alopecia, before and after starting specific treatment.
Journal Section:
Clinical Investigations – Research Article
References
1.
Leach
ER
, Leach
ER
. Alteridades
. Cabello mágico
[cited 2023 Mar 11]. Available from: https://alteridades.izt.uam.mx/index.php/Alte/article/view/5322.
Both
H
, Essink-Bot
ML
, Busschbach
J
, Nijsten
T
. Critical review of generic and dermatology-specific health-related quality of life instruments
. J Invest Dermatol
. 2007
;127
(12
):2726
–39
. 3.
Vañó-Galván
S
, Saceda-Corralo
D
, Blume-Peytavi
U
, Cucchía
J
, Dlova
NC
, Gavazzoni Dias
MFR
, et al. Frequency of the types of alopecia at twenty-two specialist hair clinics: a multicenter study
. Skin Appendage Disord
. 2019
;5
:309
–15
. 4.
Zhang
M
, Zhang
N
. Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People’s Republic of China
. Patient Prefer Adherence
. 2017
;11
:151
–5
. 5.
Russo
PM
, Fino
E
, Mancini
C
, Mazzetti
M
, Starace
M
, Piraccini
BM
. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety
. J Eur Acad Dermatol Venereol
. 2019
;33
(3
):608
–11
. 6.
Koo
JYM
, Shellow
WVR
, Hallman
CP
, Edwards
JE
. Alopecia areata and increased prevalence of psychiatric disorders
. Int J Dermatol
. 1994
;33
(12
):849
–50
. 7.
Dhami
L
. Psychology of hair loss patients and importance of counseling
. Indian J Plast Surg
. 2021
;54
(4
):411
–5
. 8.
Moattari
CR
, Jafferany
M
. Psychological aspects of hair disorders: consideration for dermatologists, cosmetologists, aesthetic, and plastic surgeons
. Skin Appendage Disord
. 2022
;8
(3
):186
–94
. 9.
Gupta
M
. Quality of life assessment in males with androgenetic alopecia–a prospective study
. Our Dermatol Online
. 2019
;10
(4
):344
–8
. 10.
Edson-Heredia
E
, Aranishi
T
, Isaka
Y
, Anderson
P
, Marwaha
S
, Piercy
J
. Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan
. J Dermatol
. 2022
;49
(6
):575
–83
. 11.
Chren
MM
, Lasek
RJ
, Flocke
SA
, Zyzanski
SJ
. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases
. Arch Dermatol
. 1997
;133
(11
):1433
–40
. 12.
Lewis
V
, Finlay
AY
. 10 years experience of the dermatology life quality Index (DLQI)
. J Investig Dermatol Symp Proc
. 2004
;9
(2
):169
–80
. 13.
Rencz
F
, Gulácsi
L
, Péntek
M
, Wikonkál
N
, Baji
P
, Brodszky
V
. Alopecia areata and health-related quality of life: a systematic review and meta-analysis
. Br J Dermatol
. 2016
;175
(3
):561
–71
. 14.
Schmidt
S
, Fischer
T
, Chren
M
, Strauss
B
, Elsner
P
. Strategies of coping and quality of life in women with alopecia
. Br J Dermatol
. 2001
;144
(5
):1038
–43
. 15.
Chernyshov
PV
, Tomas-Aragones
L
, Finlay
AY
, Manolache
L
, Marron
SE
, Sampogna
F
, et al. Quality of life measurement in alopecia areata. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes
. J Eur Acad Dermatol Venereol
. 2021
;35
(8
):1614
–21
. 16.
Basra
MKA
, Fenech
R
, Gatt
RM
, Salek
MS
, Finlay
AY
. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results
. Br J Dermatol
. 2008
;159
(5
):997
–1035
. 17.
Nijsten
TEC
, Sampogna
F
, Chren
MM
, Abeni
DD
. Testing and reducing skindex-29 using rasch analysis: skindex-17
. J Invest Dermatol
. 2006
;126
(6
):1244
–50
. 18.
Jorge
MFS
, Sousa
TD
, Pollo
CF
, Paiva
BSR
, Ianhez
M
, Boza
JC
, et al. Dimensionality and psychometric analysis of DLQI in a Brazilian population
. Health Qual Life Outcomes
. 2020
;18
(1
):268
. 19.
Sanclemente
G
, Burgos
C
, Nova
J
, Hernández
F
, González
C
, Reyes
MI
, et al. The impact of skin diseases on quality of life: a multicenter study
. Actas Dermosifiliogr
. 2017.1
;108
(3
):244
–52
. 20.
Jones-Caballero
M
, Peñas
PF
, García-Diez
A
, Chren
MM
, Badía
X
. [The Spanish version of Skindex-29. An instrument for measuring quality of life in patients with cutaneous diseases]
. Med Clin
. 2002
;118
(1
):5
–9
. 21.
Sanclemente-Mesa
G
, García
H
, Aguirre-Acevedo
D
, Jones-Caballero
M
, Lugo
L
, Escobar
C
, et al. Fiabilidad y validez de constructo de la versión colombiana del instrumento de calidad de vida Skindex-29© en Medellín, Colombia
. Iatreia
. 2017
;30
(1
):21
–33
. 22.
Vasquez
D
, Aguirre
DC
, Sanclemente
G
. Construct validity and responsiveness of the Colombian version of Skindex‐29
. Br J Dermatol
. 2019
;181
(4
):770
–7
. 23.
Dane, Ministerio de Hacienda y Crédito Publico. Evaluación de la estratificación socioeconómica como instrumento de clasificación de los usuarios y herramienta de asignación de subsidios y contribuciones a los servicios públicos domiciliarios. [Accessed apr 10 2024]. Available from: http://www.dane.gov.co/files/geoestadistica/EvaluacionEstratificaicon.pdf
24.
Restrepo
C
, Escobar Valencia
C
, García García
HI
, Lugo Agudelo
LH
, Sanclemente Mesa
G
, Lugo Agudelo
LH
. Instrumentos de evaluación de la calidad de vida en dermatología
. Iatreia
. 2013
;26
(4
):467
–75
. 25.
Cohen
J
, Hillsdale
NJ
. Laurence erlbaum and associates
. In: Statistical power for the behaviour sciences
. 1977
. p. 474
[cited 2024 Jul 6]. Available from: http://www.sciencedirect.com:5070/book/9780121790608/statistical-power-analysis-for-the-behavioral-sciences26.
R: a language and environment for statistical computing
[cited 2023 Mar 27]; Available from: http://www.gnu.org/copyleft/gpl.html27.
Husted
JA
, Cook
RJ
, Farewell
VT
, Gladman
DD
. Methods for assessing responsiveness: a critical review and recommendations
. J Clin Epidemiol
. 2000
;53
(5
):459
–68
. 28.
Vañó-Galván
S
, Molina-Ruiz
AM
, Serrano-Falcón
C
, Arias-Santiago
S
, Rodrigues-Barata
AR
, Garnacho-Saucedo
G
, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients
. J Am Acad Dermatol
. 2014
;70
(4
):670
–8
. 29.
Murugappan
MN
, King-Kallimanis
BL
, Mangir
C
, Howie
L
, Bhatnagar
V
, Beaver
JA
, et al. Floor and ceiling effects in the EORTC QLQ-C30 physical functioning subscale among patients with advanced or metastatic breast cancer
. Cancer
. 2022
;128
(4
):808
–18
. 30.
Tibaduiza
MF
, Berbeo
YK
, Ton
CM
, Aguirre-Acevedo
DC
, Sanclemente
G
. Responsiveness of the Colombian Spanish version of the DLQI in psoriasis patients with biologic therapy
. Actas Dermosifiliogr
. 2024
;115
(3
):316
–20
. 31.
Zhuang
XS
, Zheng
YY
, Xu
JJ
, Fan
WX
. Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients
. Exp Ther Med
. 2013
;6
(2
):542
–6
. 32.
Gonul
M
, Cemil
BC
, Ayvaz
HH
, Cankurtaran
E
, Ergin
C
, Gurel
MS
. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata
. Bras Dermatol
. 2018
;93
(5
):651
–8
. 33.
Katoulis
AC
, Christodoulou
C
, Liakou
AI
, Kouris
A
, Korkoliakou
P
, Kaloudi
E
, et al. Quality of life and psychosocial impact of scarring and non-scarring alopecia in women
. J Dtsch Dermatol Ges
. 2015
;13
(2
):137
–42
. 34.
Mesinkovska
N
, Craiglow
B
, Ball
SG
, Morrow
P
, Smith
SG
, Pierce
E
, et al. The invisible impact of a visible disease: psychosocial impact of alopecia areata
. Dermatol Ther
. 2023
;13
(7
):1503
–15
. 35.
Senna
M
, Ko
J
, Glashofer
M
, Walker
C
, Ball
S
, Edson-Heredia
E
, et al. Predictors of QOL in patients with alopecia areata
. J Invest Dermatol
. 2022
;142
(10
):2646
–50.e3
. 36.
Gelhorn
HL
, Cutts
K
, Edson-Heredia
E
, Wright
P
, Delozier
A
, Shapiro
J
, et al. The relationship between patient-reported severity of hair loss and health-related quality of life and treatment patterns among patients with alopecia areata
. Dermatol Ther
. 2022
;12
(4
):989
–97
. 37.
Abedini
R
, Hallaji
Z
, Lajevardi
V
, Nasimi
M
, Karimi Khaledi
M
, Tohidinik
HR
. Quality of life in mild and severe alopecia areata patients
. Int J Womens Dermatol
. 2018
;4
(2
):91
–4
. 38.
Toussi
A
, Barton
VR
, Le
ST
, Agbai
ON
, Kiuru
M
. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review
. J Am Acad Dermatol
. 2021
;85
(1
):162
–75
. 39.
Van Dalen
M
, Muller
KS
, Kasperkovitz-Oosterloo
JM
, Okkerse
JME
, Pasmans
SGMA
. Anxiety, depression, and quality of life in children and adults with alopecia areata: a systematic review and meta-analysis
. Front Med
. 2022
;9
:1054898
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
